Medodermone (Clobetasol Propionate)

Medodermone, a high‑potency topical corticosteroid, is indicated for several inflammatory skin disorders.

• Psoriasis: reduces plaque thickness, scaling and erythema in plaque psoriasis.
• Atopic dermatitis: alleviates itching, redness and inflammation in moderate to severe eczema.
• Lichen planus: diminishes lesions and associated discomfort in cutaneous lichen planus.
• Discoid lupus erythematosus: controls inflammation and prevents new lesion formation in cutaneous lupus.

• Clobetasol Propionate penetrates the epidermis and binds to intracellular glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it modulates gene transcription, suppressing pro‑inflammatory cytokines, chemokines and adhesion molecules. This reduces leukocyte infiltration, edema, and keratinocyte proliferation, delivering potent anti‑inflammatory and immunosuppressive effects on the skin.

Topical application of Medodermone may be associated with local and systemic adverse reactions.

Common Side Effects

• Burning or stinging sensation
• Pruritus
• Dryness or flaking of skin
• Skin atrophy
• Folliculitis
• Telangiectasia

Serious or Rare Side Effects

• Hypothalamic‑pituitary‑adrenal axis suppression
• Cushing’s syndrome
• Secondary bacterial, fungal or viral skin infection
• Severe allergic contact dermatitis
• Systemic corticosteroid toxicity (e.g., hyperglycemia)
• Pigmentary changes or hypopigmentation

When using Medodermone, careful attention to application and patient factors helps minimize risks.

• Apply only to affected skin areas: limit to prescribed sites.
• Avoid use on face, groin or axillae unless directed: these areas are more susceptible to irritation.
• Do not apply to broken or infected skin: may increase systemic absorption.
• Limit duration of therapy: usually no longer than 2‑4 weeks unless supervised.
• Monitor for signs of systemic effects: such as weight gain, hypertension or glucose intolerance.
• Store at room temperature: keep in original container, protect from moisture and light.

Medodermone can interact with other agents that affect corticosteroid absorption or systemic activity.

Major Interactions (Avoid)

• Occlusive dressings: increase percutaneous absorption, raising risk of systemic effects.
• Concurrent systemic corticosteroids: additive immunosuppression and adrenal suppression.

Moderate Interactions (Monitor Closely)

• Topical antifungal or antibacterial agents: may alter skin barrier and affect absorption.
• CYP3A4 inducers (e.g., rifampin) if systemic absorption occurs: may reduce steroid efficacy.
• Phototherapy (UVB): may enhance skin irritation.
• Other potent topical steroids used on adjacent areas: risk of cumulative exposure.